Dr. Neil J. Campbell Is Appointed Marizyme CEO, President and Member of Board of Directors

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

November 6, 2020

Dr. Neil J. Campbell has been appointed Marizyme CEO and President and member of their board of directors. The news was announced today.

Dr. Neil J. Campbell has more than 35 years of successful experience with public and private companies in the life sciences, medical, health tech, nanotechnology, artificial intelligence, and high-performance computing technologies, including with IGEN International (now Roche), Celera Genomics, and Abbott Laboratories. He also has prior institutional investment experience as a partner in venture capital and operating partner and industry advisor in private equity.

James Sapirstein, Marizyme’s Executive Chairman, who also served as Interim CEO, commented, “Neil is a strong leader who will take Marizyme to the next level by advancing the company’s clinical programs and develop strategies and execution to unlock shareholder value.  His extensive executive experience in the life sciences and medical industries, as well as his investment background, will guide Marizyme as the company grows its life science assets and seeks to elevate its financial position.”

“I am very excited to join the Marizyme team,” said Dr. Campbell. “Marizyme has great potential in the pipeline of products in development and the early success of products like DuraGraft®, which has been shown to reduce graft failure in bypass surgery and significantly reduce major adverse cardiac events such as repeat revascularization and myocardial infarction.”

Dr. Campbell currently serves as Chairman of Mosaigen®, a commercial development company, and RespaRx™, a medical device company. Previously, Dr. Campbell served as Chairman, CEO, and founder of Celios®, a respiratory device company that was acquired by a private investment group. Prior to founding Celios, Dr. Campbell was Co-founder, President and CEO of Helomics, a personalized healthcare company focused on next-generation therapeutics and diagnostics.

Dr. Campbell has held senior executive positions at SuperNova Diagnostics, EntreMed Pharmaceuticals, Life Technologies, IGEN International (now Roche), Celera Genomics, and Abbott Laboratories. He has also held academic positions at Johns Hopkins University and Medical Institutes, Hong Kong University of Science and Tech, University of Liverpool (UK), University of Baltimore and Duquesne University in Pittsburgh, PA.

Dr. Campbell earned his B.S. from Norwich University; his M.A. and M.B.A. from Webster University; and his Doctorate from the University of Liverpool in the UK.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.